Immuneering to Present at the Jefferies Global Healthcare Conference
Immuneering to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
馬薩諸塞州劍橋市，2024年5月29日（環球新聞社）——臨床癌症公司Immuneering Corporation（納斯達克代碼：IMRX）旨在發展和商業化廣泛癌症患者的通用RAS / RAF藥物，今天宣佈管理層將參加將於2024年6月5日至6日在紐約市萬豪酒店舉行的傑富瑞全球醫療保健會議，討論該公司的管道，平台和業務策略。本次活動的參與者包括共同創始人兼首席執行官Ben Zeskind以及首席會計官，財務主管Mallory Morales。
Format: Company Presentation and 1x1 Investor Meetings
格式：公司介紹和1x1投資者會議
Presentation: June 5 from 4:30 – 4:55 pm ET in Track 2
演示：6月5日下午4:30至4:55 ET 2號軌道
The presentations will be webcast live and archived in the Investor Relations section of Immuneering's website at Events & Presentations | Immuneering Corporation.
演示將在Immuneering網站的投資者關係部分現場網絡直播和存檔，網址爲 活動和演示 | Immuneering Corporation.
About Immuneering Corporation
關於Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The Company's development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Immuneering是一家臨床階段的腫瘤學公司，旨在爲患有RAS突變的晚期實體瘤患者開發和商業化廣泛人群的通用RAS / RAF藥物，最初旨在開發一種通用RAS療法。公司旨在通過深度循環抑制MAPK通路來實現通用活性，影響癌細胞而保留健康細胞。 Immuneering的主要產品候選藥物IMM-1-104是口服、一日一次的深循環抑制劑，目前正在進行一項針對攜帶RAS突變的晚期實體瘤患者的1 / 2a期試驗。 IMM-6-415是一種口服、每日兩次的深循環抑制劑，目前正在進行一項針對攜帶RAS或RAF突變的晚期實體瘤患者的1 / 2a期試驗。公司的開發管道還包括幾個早期項目。有關更多信息，請訪問www.immuneering.com.
Media Contact:
Gina Nugent
gina@nugentcommunications.com
媒體聯繫人：
Gina Nugent
gina@nugentcommunications.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
投資者聯繫人：
勞倫斯·瓦茨
619-916-7620
laurence@newstreetir.com
譯文內容由第三人軟體翻譯。